Related Experiment Videos
Paroxetine in the treatment of melancholia and severe depression
J Tignol1, M J Stoker, G C Dunbar
1Université de Bordeaux, France.
Abstract:
Meta-analyses of the worldwide paroxetine database assessed the efficacy of this compound in the treatment of both DSM-III defined melancholia and hospitalised patients with severe depression (HAMD > or = 25). The analysis for melancholia included 178 paroxetine treated patients and 66 patients treated with placebo. Paroxetine was significantly superior to placebo in the treatment of melancholia and a clear dose-response relationship was established. The meta-analysis for severely depressed hospitalised patients included 109 paroxetine treated patients and 107 patients treated with a tricyclic/tetracyclic control. Paroxetine and active controls showed comparable efficacy in the treatment of severely depressed hospitalised patients.
Insights
Paroxetine effectively treats melancholia, showing a dose-response relationship. It also demonstrates comparable efficacy to other antidepressants in severely depressed hospitalised patients.
Area of Science:
- Psychiatry
- Clinical Pharmacology
- Evidence-Based Medicine
Background:
- Meta-analyses are crucial for synthesizing evidence on antidepressant efficacy.
- Paroxetine is a selective serotonin reuptake inhibitor (SSRI) used for depression.
- Understanding treatment efficacy in specific depression subtypes is essential.
Purpose of the Study:
- To assess the efficacy of paroxetine in melancholia and severe depression using meta-analysis.
- To establish a dose-response relationship for paroxetine in melancholia.
- To compare paroxetine's efficacy against placebo and active controls in different depression populations.
Main Methods:
- Meta-analysis of worldwide paroxetine clinical trial data.
- Inclusion of patients meeting DSM-III criteria for melancholia.
- Comparison of paroxetine with placebo for melancholia and with tricyclic/tetracyclic controls for severe depression.
Main Results:
- Paroxetine demonstrated statistically significant superiority over placebo in treating melancholia.
- A clear dose-response relationship was observed for paroxetine in melancholic patients.
- Paroxetine showed comparable efficacy to tricyclic/tetracyclic antidepressants in severely depressed, hospitalised patients.
Conclusions:
- Paroxetine is an effective treatment for melancholia with a dose-dependent effect.
- Paroxetine offers comparable efficacy to established antidepressants for severe, hospitalised depression.
- These findings support paroxetine's role in managing specific depressive disorders.